EGFR and non-small cell lung carcinoma: The CheckMate722 trial included 294 patients with EGFR-mutated NSCLC who had progressed with first- or second-generation EGFR-TKIs and did not have the T790M mutation and patients who had progressed with osimertinib with or without the T790M mutation.